Antibody responses of burned patients immunized with a polyvalent <i>Pseudomonas</i> vaccine

Jones, Rhys

doi:10.1017/s0022172400053973

Cited by 20 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the mode in which a P. aeruginosa vaccine is employed would depend upon the immune status of the individual. Active vaccination is a feasible approach in certain high-risk groups, such as in burned or surgical patients who have been shown to mount a good humoral immune response to parenterally administered P. aeruginosa antigens (10,25,26). Immunosuppressed patients, on the other hand, would not be expected to benefit greatly from immunization due to their depressed capacity to mount an antibody response (9,27,28).…”

Section: Discussionmentioning

confidence: 99%

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Cryz¹,

Fürer²,

Cross³

et al. 1987

J. Clin. Invest.

View full text Add to dashboard Cite

Lipid A-free polysaccharide (PS) isolated from Pseudomonas aeruginosa immunotype 5 lipopolysaccharide (LPS) was covalently coupled to toxin A via reductive amination. The PS-toxin A conjugate was comprised of 29.8% PS and 70.2% toxin A, possessed a molecular weight of > 1 X 106, was nontoxic for animals and was nonpyrogenic for rabbits at a dose of 50 tg/kg body wt when administered intravenously. The conjugate evoked only mild, transient reactions upon subcutaneous administration to human volunteers. Vaccination engendered immunoglobulin G (IgG) antibody, which neutralized the cytotoxic effect of toxin A and promoted the uptake and killing of P. aeruginosa in the presence of human polymorphonuclear leukocytes. Passively transferred IgG isolated from the serum of immunized donors was far more effective at preventing fatal P. aeruginosa burn wound sepsis than paired preimmunization serum. These studies establish the potential usefulness of such a PS-toxin A conjugate as a vaccine against P. aeruginosa.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Cryz¹,

Fürer²,

Cross³

et al. 1987

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Since no cross reaction was observed between different serotypes of P. aeruginosa (Fisher et al 1969;Knirel 1990;Odeh 2002; this study), thus a protective vaccine against P. aeruginosa would have to be a polyvalent vaccine (PEV). In previous studies, PEV using LPS elicited high levels of anti-PEV in rabbits (MacIntyre et al 1985) and human (Jones 1979;MacIntyre et al 1985), which was sufficient to protect patients at high risk from P. aeruginosa infection (Jones et al 1976;Roe and Jones 1983).…”

Section: Discussionmentioning

confidence: 89%

LPS-based conjugate vaccines composed of O-polysaccharide from Pseudomonas aeruginosa IATS 6 and 11 bound to a carrier protein

Al‐Zeer

Masoud

2007

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Lipopolysaccharide (LPS) is the major surface antigen of Pseudomonas aeruginosa and elicits protective antibodies in animals. No cross reaction was observed between LPSs of P. aeruginosa International Antigenic Typing Scheme (IATS) 6 and 11 strains using rabbit polyclonal antibodies raised against the whole cells. The Opolysaccharides (O-PSs) from IATS 6 and 11, the antigenic determinant of LPS, were directly coupled to bovine serum albumin (BSA) by carbodiimide mediated condensation reaction. The molar ratios of saccharide repeating units to BSA in the prepared conjugates were 15:1 and 26:1 for IATS 6 and 11 conjugates, respectively. Mice were immunized with the conjugates emulsified with monophosphoryl lipid A (MPL), Freund, and Alum adjuvants. The conjugates emulsified with MPL adjuvant elicited the highest IgM antibody, followed by Freund. While both MPL and Freund adjuvants elicited high IgG antibody. Good correlation was observed between the IgG and IgM levels with the bactericidal activities of the sera against homologous strains. In addition, immunization of mice with the prepared conjugates emulsified with MPL and Freund adjuvants provided high protection against ten times the LD 50 of P. aeruginsoa IATS 6 and 11, which showed a good correlations with the IgG titer.

show abstract

“…A 16-part polyvalent pseudomonas extract vaccine (PEV) has been used for immunising burned patients against Pseudomonas aeruginosa in a prophylactic trial (Jones, 1979). It has also been shown that immunoglobulin from healthy volunteers immunised with PEV conferred passive immunity against pseudomonas septicaemia in severely burned children and in adults at risk from P .…”

Section: Introductionmentioning

confidence: 99%

Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine

Barclay

Yap

McClelland

et al. 1986

Journal of Medical Microbiology

Self Cite

View full text Add to dashboard Cite

Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine

Abstract: SUMMARYIn two controlled clinical trials of a polyvalent pseudomonas vaccine, vaccinated burned patients showed higher antibody titres to the 16 antigens in the vaccine and higher titres of a passively transferable protective antibody than was found in unvaccinated burned patients.

Cited by 20 publications

References 6 publications

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

LPS-based conjugate vaccines composed of O-polysaccharide from Pseudomonas aeruginosa IATS 6 and 11 bound to a carrier protein

Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine

Contact Info

Product

Resources

About